ArticleTranslational lung cancer research2026
Elevated baseline C-reactive protein predicts poorer survival in lung cancer: a 22-year retrospective cohort study.
Article in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Baseline Neutrophil-to-Lymphocyte Ratio and Two-Year Incident Distant Metastasis in Stage I-III Lung Cancer: A Single-Center Retrospective Cohort Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Systemic inflammation has been implicated in cancer progression and C-reactive protein (CRP) is an established inflammatory biomarker. We investigated clinical and pathological factors associated with elevated baseline CRP in lung cancer and evaluated their relationships with survival outcomes. Methods: We retrospectively reviewed 1,339 patients with newly diagnosed lung cancer at Peking Union Medical College Hospital (PUMCH) between October 2000 and March 2022. Baseline serum CRP was measured prior to anti-tumor therapy; CRP ≥10 mg/L was defined as elevated. Patient demographics, tumor characteristics and treatment variables were compared by CRP level. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier analysis with log-rank tests. Cox proportional hazards models were used to identify independent prognostic factors for OS and PFS. The study was approved by the ethical review committee of PUMCH. Results: Elevated CRP (≥10 mg/L) was present in 41.0% of patients at diagnosis. High CRP was significantly associated with adverse clinical features, including older age, male sex, smoking, alcohol use, advanced stage III-IV disease, Eastern Cooperative Oncology Group (ECOG) performance status score 2-4, absence of driver gene mutations, positive programmed death ligand 1 (PD-L1) expression, presence of metastases and receipt of immunotherapy. In Kaplan-Meier analyses, patients with high CRP had significantly shorter OS and PFS than those with CRP <10 mg/L (median OS 19.0 Conclusions: Baseline CRP elevation in lung cancer correlates with more aggressive disease characteristics and independently portends inferior survival. CRP, as an inexpensive routine test, could aid in risk stratification and prognostication. Integrating CRP into clinical decision-making may improve identification of high-risk patients who might benefit from intensified or alternative therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.